+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-obesity Prescription Drugs Market Research Report by Drug Class, by Age Group, by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4904662
  • Report
  • February 2021
  • Region: Global
  • 184 pages
  • 360iResearch™
UP TO OFF
until Jun 30th 2021
The Global Anti-obesity Prescription Drugs Market to Grow USD 6,994.08 Million by 2025, at a CAGR of 7.08%

FEATURED COMPANIES

  • 7TM Pharma A/S
  • Arrowhead Pharmaceuticals
  • Bristol-Myers Squibb Co
  • Eisai Co., Ltd
  • GlaxoSmithKline PLC
  • Norgine BV
Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Anti-obesity Prescription Drugs Market is expected to grow from USD 4,965.82 Million in 2020 to USD 6,994.08 Million by the end of 2025.
2. The Global Anti-obesity Prescription Drugs Market is expected to grow from EUR 4,354.12 Million in 2020 to EUR 6,132.54 Million by the end of 2025.
3. The Global Anti-obesity Prescription Drugs Market is expected to grow from GBP 3,870.82 Million in 2020 to GBP 5,451.84 Million by the end of 2025.
4. The Global Anti-obesity Prescription Drugs Market is expected to grow from JPY 529,978.82 Million in 2020 to JPY 746,445.56 Million by the end of 2025.
5. The Global Anti-obesity Prescription Drugs Market is expected to grow from AUD 7,211.03 Million in 2020 to AUD 10,156.33 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Anti-obesity Prescription Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the Anti-obesity Prescription Drugs Market is examined across Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate.
  • Based on Age Group, the Anti-obesity Prescription Drugs Market is examined across Adult and Pediatric.
  • Based on Distribution Channel, the Anti-obesity Prescription Drugs Market is examined across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Geography, the Anti-obesity Prescription Drugs Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-obesity Prescription Drugs Market including 7TM Pharma A/S, Akrimax Pharmaceuticals Inc, Alizyme PLC, Arena Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Co, C.H. Boehringer Sohn AG & Ko. KG, Cadila Healthcare Limited, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Norgine BV, Novo Nordisk A/s, Orexigen Therapeutics, Inc, Orexigen Therapeutics, Inc., Pfizer Inc,, Rhythm Pharmaceuticals, Inc., Shionogi USA Inc, Takeda Pharmaceutical Company Limited, Vivus Inc, VIVUS, Inc, and Zafgen Inc.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. The ongoing research amplifies the research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-obesity Prescription Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Anti-obesity Prescription Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-obesity Prescription Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-obesity Prescription Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Anti-obesity Prescription Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Anti-obesity Prescription Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global Anti-obesity Prescription Drugs Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 7TM Pharma A/S
  • Arrowhead Pharmaceuticals
  • Bristol-Myers Squibb Co
  • Eisai Co., Ltd
  • GlaxoSmithKline PLC
  • Norgine BV
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Age Group Outlook
3.5. Distribution Channel Outlook
3.6. Geography Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of obesity and related chronic diseases
5.1.1.2. Growing unhealthy and sedentary lifestyle
5.1.1.3. Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
5.1.2. Restraints
5.1.2.1. Side effect related to anti-obesity drugs
5.1.3. Opportunities
5.1.3.1. Introduction of novel anti-obesity drugs
5.1.4. Challenges
5.1.4.1. Availability of alternative treatment options
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Global Anti-obesity Prescription Drugs Market, By Drug Class
6.1. Introduction
6.2. Bupropion and Naltrexone
6.3. Liraglutide
6.4. Lorcaserin
6.5. Orlistat
6.6. Phentermine and Topiramate

7. Global Anti-obesity Prescription Drugs Market, By Age Group
7.1. Introduction
7.2. Adult
7.3. Pediatric

8. Global Anti-obesity Prescription Drugs Market, By Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy

9. Americas Anti-obesity Prescription Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Anti-obesity Prescription Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. South Korea
10.10. Thailand

11. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis
12.4. Competitor SWOT Analysis
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. 7TM Pharma A/S
13.2. Akrimax Pharmaceuticals Inc
13.3. Alizyme PLC
13.4. Arena Pharmaceuticals, Inc
13.5. Arrowhead Pharmaceuticals
13.6. Bayer AG
13.7. Bristol-Myers Squibb Co
13.8. C.H. Boehringer Sohn AG & Ko. KG
13.9. Cadila Healthcare Limited
13.10. Currax Pharmaceuticals LLC
13.11. Eisai Co., Ltd
13.12. F. Hoffmann-La Roche AG
13.13. GlaxoSmithKline PLC
13.14. Merck & Co.
13.15. Norgine BV
13.16. Novo Nordisk A/s
13.17. Orexigen Therapeutics, Inc
13.18. Orexigen Therapeutics, Inc.
13.19. Pfizer Inc,
13.20. Rhythm Pharmaceuticals, Inc.
13.21. Shionogi USA Inc
13.22. Takeda Pharmaceutical Company Limited
13.23. Vivus Inc
13.24. VIVUS, Inc
13.25. Zafgen Inc

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
Figure 1. Global Anti-Obesity Prescription Drugs Market: Research Process
Figure 2. Global Anti-Obesity Prescription Drugs Market: Research Execution
Figure 3. Global Anti-Obesity Prescription Drugs Market Size, 2020 Vs 2025 (USD Million)
Figure 4. Global Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2020 (USD Million)
Figure 5. Global Anti-Obesity Prescription Drugs Market Size, by Age Group, 2020 (USD Million)
Figure 6. Global Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2020 (USD Million)
Figure 7. Global Anti-Obesity Prescription Drugs Market Size, by Geography, 2020 (USD Million)
Figure 8. Global Anti-Obesity Prescription Drugs Market Size, 2018-2025 (USD Million)
Figure 9. Global Anti-Obesity Prescription Drugs Market Size, by Geography, 2020 Vs 2025 (%)
Figure 10. Global Anti-Obesity Prescription Drugs Market Size, by Geography, 2020 Vs 2025 (USD Million)
Figure 11. Competitive Strategic Window for Global Anti-Obesity Prescription Drugs Market Size, by Geography, 2025
Figure 12. Global Anti-Obesity Prescription Drugs Market: Market Dynamics
Figure 13. Global Anti-Obesity Prescription Drugs Market: Porters Five Forces Analysis
Figure 14. Global Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2020 Vs 2025 (%)
Figure 15. Global Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2020 Vs 2025 (USD Million)
Figure 16. Competitive Strategic Window for Global Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2025
Figure 17. Global Anti-Obesity Prescription Drugs Market Size, by Bupropion and Naltrexone, 2020 Vs 2025 (USD Million)
Figure 18. Global Anti-Obesity Prescription Drugs Market Size, by Liraglutide, 2020 Vs 2025 (USD Million)
Figure 19. Global Anti-Obesity Prescription Drugs Market Size, by Lorcaserin, 2020 Vs 2025 (USD Million)
Figure 20. Global Anti-Obesity Prescription Drugs Market Size, by Orlistat, 2020 Vs 2025 (USD Million)
Figure 21. Global Anti-Obesity Prescription Drugs Market Size, by Phentermine and Topiramate, 2020 Vs 2025 (USD Million)
Figure 22. Global Anti-Obesity Prescription Drugs Market Size, by Age Group, 2020 Vs 2025 (%)
Figure 23. Global Anti-Obesity Prescription Drugs Market Size, by Age Group, 2020 Vs 2025 (USD Million)
Figure 24. Competitive Strategic Window for Global Anti-Obesity Prescription Drugs Market Size, by Age Group, 2025
Figure 25. Global Anti-Obesity Prescription Drugs Market Size, by Adult, 2020 Vs 2025 (USD Million)
Figure 26. Global Anti-Obesity Prescription Drugs Market Size, by Pediatric, 2020 Vs 2025 (USD Million)
Figure 27. Global Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2020 Vs 2025 (%)
Figure 28. Global Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2020 Vs 2025 (USD Million)
Figure 29. Competitive Strategic Window for Global Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2025
Figure 30. Global Anti-Obesity Prescription Drugs Market Size, by Hospital Pharmacy, 2020 Vs 2025 (USD Million)
Figure 31. Global Anti-Obesity Prescription Drugs Market Size, by Online Pharmacy, 2020 Vs 2025 (USD Million)
Figure 32. Global Anti-Obesity Prescription Drugs Market Size, by Retail Pharmacy, 2020 Vs 2025 (USD Million)
Figure 33. Americas Anti-Obesity Prescription Drugs Market Size, by Geography, 2020 Vs 2025 (%)
Figure 34. Americas Anti-Obesity Prescription Drugs Market Size, by Geography, 2020 Vs 2025 (USD Million)
Figure 35. Competitive Strategic Window for Americas Anti-Obesity Prescription Drugs Market Size, by Geography, 2025
Figure 36. Argentina Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 37. Brazil Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 38. Canada Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 39. Mexico Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 40. United States Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 41. Asia-Pacific Anti-Obesity Prescription Drugs Market Size, by Geography, 2020 Vs 2025 (%)
Figure 42. Asia-Pacific Anti-Obesity Prescription Drugs Market Size, by Geography, 2020 Vs 2025 (USD Million)
Figure 43. Competitive Strategic Window for Asia-Pacific Anti-Obesity Prescription Drugs Market Size, by Geography, 2025
Figure 44. Australia Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 45. China Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 46. India Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 47. Indonesia Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 48. Japan Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 49. Malaysia Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 50. Philippines Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 51. South Korea Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 52. Thailand Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 53. Europe, Middle East & Africa Anti-Obesity Prescription Drugs Market Size, by Geography, 2020 Vs 2025 (%)
Figure 54. Europe, Middle East & Africa Anti-Obesity Prescription Drugs Market Size, by Geography, 2020 Vs 2025 (USD Million)
Figure 55. Competitive Strategic Window for Europe, Middle East & Africa Anti-Obesity Prescription Drugs Market Size, by Geography, 2025
Figure 56. France Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 57. Germany Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 58. Italy Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 59. Netherlands Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 60. Qatar Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 61. Russia Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 62. Saudi Arabia Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 63. South Africa Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 64. Spain Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 65. United Arab Emirates Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 66. United Kingdom Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD Million)
Figure 67. Global Anti-Obesity Prescription Drugs Market: Fpnv Positioning Matrix
Figure 68. Global Anti-Obesity Prescription Drugs Market: Market Share Analysis
Figure 69. Global Anti-Obesity Prescription Drugs Market: Competitor SWOT Analysis
Figure 70. Competitive Scenario Analysis in Global Anti-Obesity Prescription Drugs Market, by Type

List of Tables
Table 1. Currency Conversion Rates
Table 2. Global Anti-Obesity Prescription Drugs Market Size, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 3. Global Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 4. Global Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 5. Global Anti-Obesity Prescription Drugs Market Size, by Bupropion and Naltrexone, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 6. Global Anti-Obesity Prescription Drugs Market Size, by Liraglutide, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 7. Global Anti-Obesity Prescription Drugs Market Size, by Lorcaserin, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 8. Global Anti-Obesity Prescription Drugs Market Size, by Orlistat, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 9. Global Anti-Obesity Prescription Drugs Market Size, by Phentermine and Topiramate, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 10. Global Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 11. Global Anti-Obesity Prescription Drugs Market Size, by Adult, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 12. Global Anti-Obesity Prescription Drugs Market Size, by Pediatric, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 13. Global Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 14. Global Anti-Obesity Prescription Drugs Market Size, by Hospital Pharmacy, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 15. Global Anti-Obesity Prescription Drugs Market Size, by Online Pharmacy, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 16. Global Anti-Obesity Prescription Drugs Market Size, by Retail Pharmacy, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 17. Americas Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 18. Americas Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 19. Americas Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 20. Americas Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 21. Argentina Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 22. Argentina Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 23. Argentina Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 24. Brazil Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 25. Brazil Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 26. Brazil Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 27. Canada Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 28. Canada Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 29. Canada Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 30. Mexico Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 31. Mexico Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 32. Mexico Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 33. United States Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 34. United States Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 35. United States Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 36. Asia-Pacific Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 37. Asia-Pacific Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 38. Asia-Pacific Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 39. Asia-Pacific Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 40. Australia Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 41. Australia Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 42. Australia Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 43. China Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 44. China Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 45. China Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 46. India Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 47. India Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 48. India Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 49. Indonesia Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 50. Indonesia Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 51. Indonesia Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 52. Japan Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 53. Japan Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 54. Japan Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 55. Malaysia Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 56. Malaysia Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 57. Malaysia Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 58. Philippines Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 59. Philippines Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 60. Philippines Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 61. South Korea Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 62. South Korea Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 63. South Korea Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 64. Thailand Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 65. Thailand Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 66. Thailand Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 67. Europe, Middle East & Africa Anti-Obesity Prescription Drugs Market Size, by Geography, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 68. Europe, Middle East & Africa Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 69. Europe, Middle East & Africa Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 70. Europe, Middle East & Africa Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 71. France Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 72. France Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 73. France Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 74. Germany Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 75. Germany Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 76. Germany Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 77. Italy Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 78. Italy Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 79. Italy Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 80. Netherlands Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 81. Netherlands Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 82. Netherlands Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 83. Qatar Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 84. Qatar Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 85. Qatar Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 86. Russia Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 87. Russia Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 88. Russia Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 89. Saudi Arabia Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 90. Saudi Arabia Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 91. Saudi Arabia Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 92. South Africa Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 93. South Africa Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 94. South Africa Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 95. Spain Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 96. Spain Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 97. Spain Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 98. United Arab Emirates Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 99. United Arab Emirates Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 100. United Arab Emirates Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 101. United Kingdom Anti-Obesity Prescription Drugs Market Size, by Drug Class, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 102. United Kingdom Anti-Obesity Prescription Drugs Market Size, by Age Group, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 103. United Kingdom Anti-Obesity Prescription Drugs Market Size, by Distribution Channel, 2018-2025 (USD/EUR/GBP/JPY/AUD Million)
Table 104. Global Anti-Obesity Prescription Drugs Market: Scores
Table 105. Global Anti-Obesity Prescription Drugs Market: Business Strategy
Table 106. Global Anti-Obesity Prescription Drugs Market: Product Satisfaction
Table 107. Global Anti-Obesity Prescription Drugs Market: Ranking
Table 108. Global Anti-Obesity Prescription Drugs Market: Merger & Acquisition
Table 109. Global Anti-Obesity Prescription Drugs Market: Agreement, Collaboration, & Partnership
Table 110. Global Anti-Obesity Prescription Drugs Market: New Product Launch & Enhancement
Table 111. Global Anti-Obesity Prescription Drugs Market: Investment & Funding
Table 112. Global Anti-Obesity Prescription Drugs Market: Award, Recognition, & Expansion
Table 113. Global Anti-Obesity Prescription Drugs Market: License & Pricing
Note: Product cover images may vary from those shown
  • 7TM Pharma A/S
  • Akrimax Pharmaceuticals Inc
  • Alizyme PLC
  • Arena Pharmaceuticals, Inc
  • Arrowhead Pharmaceuticals
  • Bayer AG
  • Bristol-Myers Squibb Co
  • C.H. Boehringer Sohn AG & Ko. KG
  • Cadila Healthcare Limited
  • Currax Pharmaceuticals LLC
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co.
  • Norgine BV
  • Novo Nordisk A/s
  • Orexigen Therapeutics, Inc
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc,
  • Rhythm Pharmaceuticals, Inc.
  • Shionogi USA Inc
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc
  • VIVUS, Inc
  • Zafgen Inc
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll